New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

• Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented
• 124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be featured
• New insights into disease characteristics in IgAN and C3G inform future research and treatment approaches
  

Basel, May 26, 2026 – Novartis will present data from 15 abstracts from its kidney portfolio at this year’s European Renal Association (ERA) Congress in Glasgow, June 3-6. The presentations reinforce our ambition to advance scientific understanding across progressive immune-mediated kidney diseases and support the evolution of kidney care.

Presentations include late-breaking Phase III results for Vanrafia^® (atrasentan) and Fabhalta^® (iptacopan), along with extended follow-up data from the investigational anti-APRIL therapy zigakibart in IgA nephropathy (IgAN). Separate analyses will also explore disease characteristics in IgAN and C3 glomerulopathy (C3G).

“At ERA this year, Novartis will present important late-stage and long-term data in IgAN, alongside broader insights across our kidney disease portfolio,” said Ruchira Glaser, MD, MS, Global Head, Cardiovascular, Renal and Metabolic Development, Novartis. “Together, these findings reflect our continued innovation and a science-driven approach to generating evidence that informs the future of kidney care.”

Key abstracts accepted by ERA include:

Abstract Title	Abstract Number/Presentation Details
Fabhalta® (iptacopan)
Iptacopan achieves near-normal kidney function decline in prespecified IgA nephropathy (IgAN) patient subgroups: APPLAUSE-IgAN final data	Abstract # ERA26-LBCT-189 Late‑Breaker Oral Presentation June 4, 12:30–12:45 pm BST
IgA Nephropathy Insights from Treatment Experience (IgNITE): A multi-country data integration approach to advance IgA nephropathy real-world evidence	Abstract #2379 Oral Presentation June 4, 5:57–6:03 pm BST
Early insights on first-line treatment patterns in patients with complement 3 glomerulopathy (C3G) receiving iptacopan: APPRISE-C3G data platform	Abstract #2962 Oral Presentation June 4, 11:57 am–12:03 pm BST
Vanrafia® (atrasentan)
Efficacy and safety of atrasentan treatment in participants with IgA nephropathy: 2.5-year eGFR results from the ALIGN trial	Abstract # ERA26-LBCT-101 Late‑Breaker Oral Presentation June 4, 11:15–11:30 am BST
Zigakibart
Efficacy and safety outcomes after 124 weeks of zigakibart treatment in IgA nephropathy (IgAN)	Abstract #2746 Oral Presentation June 5, 3:15–3:21 pm BST
Farabursen
Study design of a global Phase 3 trial evaluating the efficacy and safety of farabursen, an anti-miR-17 oligonucleotide, in patients with ADPKD	Abstract #3398 Oral Presentation June 4, 11:39–11:45 am BST

Novartis’ commitment to kidney diseases
Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need.

Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our portfolio targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms - whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians and policymakers, we aim to raise awareness, accelerate diagnosis, and get patients the right care, sooner.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

# # #

Novartis Media Relations E-mail: media.relations@novartis.com
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com